• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.新型头孢菌素 CXA-101 对呈现各种耐药表型（包括多重耐药）的铜绿假单胞菌的体外效力。
Antimicrob Agents Chemother. 2010 Jan;54(1):557-9. doi: 10.1128/AAC.00912-09. Epub 2009 Nov 16.
2
In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.2007 年至 2012 年加拿大 CANWARD 研究中，从加拿大医院患者分离的铜绿假单胞菌对头孢洛扎-他唑巴坦的体外活性。
Antimicrob Agents Chemother. 2013 Nov;57(11):5707-9. doi: 10.1128/AAC.01404-13. Epub 2013 Aug 12.
3
Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes.CXA-101 是一种新型头孢菌素，与他唑巴坦联合测试对具有不同耐药表型的肠杆菌科、铜绿假单胞菌和脆弱拟杆菌菌株的抗菌活性。
Antimicrob Agents Chemother. 2011 May;55(5):2390-4. doi: 10.1128/AAC.01737-10. Epub 2011 Feb 14.
4
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.作为监测项目“头孢洛扎-他唑巴坦敏感性评估项目”的一部分，对2013年至2016年在美国医院分离出的具有各种耐药模式的肠杆菌科细菌和铜绿假单胞菌进行头孢洛扎-他唑巴坦抗菌活性测试
Microb Drug Resist. 2018 Jun;24(5):563-577. doi: 10.1089/mdr.2017.0266. Epub 2017 Oct 17.
5
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.新型头孢菌素 CXA-101（FR264205）对体外筛选和重症监护病房患者抗假单胞菌治疗后产生的β-内酰胺耐药铜绿假单胞菌突变株的活性。
Antimicrob Agents Chemother. 2010 Mar;54(3):1213-7. doi: 10.1128/AAC.01104-09. Epub 2010 Jan 19.
6
Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.头孢他洛滨他唑巴坦与传统β-内酰胺类药物的比较以及头孢他洛滨他唑巴坦作为铜绿假单胞菌联合抗菌治疗替代方案的比较。
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01350-17. Print 2017 Dec.
7
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.新型抗假单胞菌头孢菌素 CXA-101（FR264205）对耐碳青霉烯类和多药耐药铜绿假单胞菌临床分离株的活性。
Antimicrob Agents Chemother. 2010 Feb;54(2):846-51. doi: 10.1128/AAC.00834-09. Epub 2009 Nov 23.
8
Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).针对2011 - 12年在欧洲医院分离出的具有不同耐药模式的铜绿假单胞菌和肠杆菌科细菌测试头孢洛扎/他唑巴坦的抗菌活性。
J Antimicrob Chemother. 2014 Oct;69(10):2713-22. doi: 10.1093/jac/dku184. Epub 2014 Jun 10.
9
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).头孢洛扎/他唑巴坦对引起欧洲尿路感染和腹腔内感染的耐药肠杆菌科细菌及铜绿假单胞菌的活性：一项抗菌药物监测计划（2012 - 2015年）的报告
J Antimicrob Chemother. 2017 May 1;72(5):1386-1395. doi: 10.1093/jac/dkx009.
10
Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients.新头孢菌素 CXA-101（FR264205）对慢性感染囊性纤维化患者分离的铜绿假单胞菌的活性。
Clin Microbiol Infect. 2010 Sep;16(9):1482-7. doi: 10.1111/j.1469-0691.2009.03130.x.

引用本文的文献

1
Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review.用于治疗儿童多重耐药革兰氏阴性菌感染的新型β-内酰胺类抗生素：一项叙述性综述
Microorganisms. 2023 Jul 13;11(7):1798. doi: 10.3390/microorganisms11071798.
2
Drug Regimens of Novel Antibiotics in Critically Ill Patients with Varying Renal Functions: A Rapid Review.不同肾功能重症患者新型抗生素的用药方案：快速综述
Antibiotics (Basel). 2022 Apr 20;11(5):546. doi: 10.3390/antibiotics11050546.
3
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.多中心评估头孢他啶-阿维巴坦和头孢洛扎坦-他唑巴坦对血液、呼吸道和伤口来源的美罗培南不敏感铜绿假单胞菌的抑制活性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00875-17. Print 2017 Oct.
4
Potency of parenteral antimicrobials including ceftolozane/tazobactam against nosocomial respiratory tract pathogens: considerations for empiric and directed therapy.包括头孢洛扎/他唑巴坦在内的肠外抗菌药物对医院获得性呼吸道病原体的抗菌效力：经验性和针对性治疗的考量
J Thorac Dis. 2017 Jan;9(1):214-221. doi: 10.21037/jtd.2017.01.26.
5
Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections.头孢洛扎/他唑巴坦与头孢他啶/阿维巴坦用于治疗复杂性腹腔内感染。
Ther Clin Risk Manag. 2016 Dec 1;12:1811-1826. doi: 10.2147/TCRM.S120811. eCollection 2016.
6
In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates.阿米卡星及对照药物对大肠杆菌、肺炎克雷伯菌和铜绿假单胞菌呼吸道及血液分离株的体外抗菌效力。
Ann Clin Microbiol Antimicrob. 2016 Jun 17;15(1):39. doi: 10.1186/s12941-016-0155-z.
7
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对耐美罗培南铜绿假单胞菌分离株的体外活性评估。
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3227-31. doi: 10.1128/AAC.02969-15. Print 2016 May.
8
Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.头孢洛扎/他唑巴坦对基因分型明确的产β-内酰胺酶大肠埃希菌的联合药效学：β-内酰胺类/β-内酰胺酶抑制剂联合用药的药代动力学/药效学见解
Antimicrob Agents Chemother. 2016 Mar 25;60(4):1967-73. doi: 10.1128/AAC.02635-15. Print 2016 Apr.
9
Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.在感染体外药代动力学模型中研究头孢洛扎坦加他唑巴坦的药效学。
Antimicrob Agents Chemother. 2015 Nov 9;60(1):515-21. doi: 10.1128/AAC.00727-15. Print 2016 Jan.
10
The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.革兰氏阴性菌中由外排介导的抗生素耐药性挑战。
Clin Microbiol Rev. 2015 Apr;28(2):337-418. doi: 10.1128/CMR.00117-14.

本文引用的文献

1
In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals.四十家美国医院成人系统分离大肠埃希菌和铜绿假单胞菌常用抗生素的体外活性和药效动力学研究。
Clin Ther. 2009 Nov;31(11):2678-88. doi: 10.1016/j.clinthera.2009.11.021.
2
Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-{beta}-lactamase-producing Pseudomonas aeruginosa.头孢菌素CXA-101（FR264205）及对照品对产超广谱β-内酰胺酶铜绿假单胞菌的活性
J Antimicrob Chemother. 2009 Aug;64(2):430-1. doi: 10.1093/jac/dkp193. Epub 2009 May 27.
3
Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.头孢菌素CXA-101（FR264205）对铜绿假单胞菌和洋葱伯克霍尔德菌群菌株及分离株的活性。
Int J Antimicrob Agents. 2009 Nov;34(5):402-6. doi: 10.1016/j.ijantimicag.2009.03.021. Epub 2009 May 9.
4
Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.铜绿假单胞菌中的超广谱头孢菌素酶
Antimicrob Agents Chemother. 2009 May;53(5):1766-71. doi: 10.1128/AAC.01410-08. Epub 2009 Mar 2.
5
Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.多黏菌素B和其他碳青霉烯类药物对铜绿假单胞菌、其他非发酵菌和气单胞菌属的抗菌活性
Diagn Microbiol Infect Dis. 2009 Apr;63(4):426-33. doi: 10.1016/j.diagmicrobio.2009.01.026. Epub 2009 Feb 26.
6
Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance.2002 - 2006年美国医院OPTAMA项目比较：聚焦革兰氏阴性菌耐药性
Ann Pharmacother. 2009 Feb;43(2):220-7. doi: 10.1345/aph.1L473. Epub 2009 Feb 3.
7
Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205.新型肠胃外抗假单胞菌头孢菌素的合成与构效关系研究：FR264205的发现
Bioorg Med Chem Lett. 2008 Sep 1;18(17):4849-52. doi: 10.1016/j.bmcl.2008.07.085. Epub 2008 Jul 24.
8
Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.美罗培南在美国医疗中心的比较活性（2007年）：启动MYSTIC计划监测的第二个十年
Diagn Microbiol Infect Dis. 2008 Jun;61(2):203-13. doi: 10.1016/j.diagmicrobio.2008.01.017. Epub 2008 Mar 10.
9
The current state of multidrug-resistant gram-negative bacilli in North America.北美多重耐药革兰氏阴性杆菌的现状。
Pharmacotherapy. 2008 Feb;28(2):235-49. doi: 10.1592/phco.28.2.235.
10
Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa.FR264205对铜绿假单胞菌AmpCβ-内酰胺酶的稳定性
Int J Antimicrob Agents. 2007 Nov;30(5):443-5. doi: 10.1016/j.ijantimicag.2007.05.019. Epub 2007 Jul 17.

新型头孢菌素 CXA-101 对呈现各种耐药表型（包括多重耐药）的铜绿假单胞菌的体外效力。

In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.

机构信息

FCCP, FIDSA, Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA.

出版信息

Antimicrob Agents Chemother. 2010 Jan;54(1):557-9. doi: 10.1128/AAC.00912-09. Epub 2009 Nov 16.

DOI:10.1128/AAC.00912-09
PMID:19917762
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2798502/
Abstract

We describe the activity of a novel cephalosporin, CXA-101 (FR26 4205), against a panel of highly resistant Pseudomonas aeruginosa isolates collected from U.S. hospitals. CXA-101 demonstrated increased potency against this population of resistant isolates, with activity that is 4- to 10-fold higher than that of comparator agents in each phenotypic category. The addition of tazobactam did not improve its activity. CXA-101 appears to be a promising addition to the category of antipseudomonal beta-lactams.

摘要

我们描述了一种新型头孢菌素 CXA-101（FR264205）对来自美国医院的一组高度耐药铜绿假单胞菌分离株的活性。CXA-101 对这组耐药分离株表现出更强的效力，其活性在每个表型类别中比对照药物高 4 至 10 倍。添加他唑巴坦并不能提高其活性。CXA-101 似乎是一种有前途的抗假单胞菌β-内酰胺类药物。